This page is a curated landing page for the Cytel deep dive and links to the original article rather than duplicating it.
Why comparator questions become more complex
JCA scoping can surface decision problems where the comparator is not a single treatment, but a set of clinically plausible options. This matters when treatment pathways are heterogeneous, standards of care differ across countries, or therapy choices are individualized at patient level.
For health technology developers, the evidence question becomes more demanding: does the available clinical evidence cover the relevant comparator bundle, or only a narrower slice of clinical practice
Implications for JCA and national HTA
The JCA can consider studies that cover only parts of a comparator bundle, but the limitations need to be transparent. Which treatment options were directly compared, which were not, and what uncertainty does this create for relative effectiveness
National HTA bodies then decide whether the evidence is sufficient for their local decision logic. In Germany, the assessment remains connected to Germany's Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), AMNOG as Germany's early benefit assessment framework, the appropriate comparator therapy, subgroups, patient-relevant endpoints and local clinical practice.
Relevance for the Delta-Dossier
Individualised comparators show why JCA does not replace AMNOG. European evidence can provide an important starting point, but it does not automatically answer the German added-benefit question.
The Delta-Dossier is not an official regulatory term, but a working term used in the German market access context for the additional national content required between the JCA dossier and the AMNOG dossier. In comparator-bundle situations, that national content may include comparator justification, subgroup interpretation, sensitivity analyses or localized real-world evidence.
Key points
- Not every PICO question can be reduced to a single comparator therapy.
- In some indications, the relevant comparator is a bundle of patient-individual treatment options.
- Clinical studies may cover only parts of this comparator bundle.
- The JCA can consider such evidence, while explicitly documenting its limitations.
- National HTA bodies decide whether the evidence is sufficient for local decision logic.
- For Germany, the AMNOG question remains tied to the appropriate comparator therapy, subgroups, patient-relevant endpoints and local robustness.